EGFR mutations as a predictive marker of cytotoxic chemotherapy

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 433-437

  Park, Jin Hyun ^a   Lee, Se Hoon ^a,b   Keam, Bhumsuk ^a,b   Kim, Tae Min ^a,b   Kim, Dong Wan ^a,b   Yang, Seok Chul ^a   Kim, Young Whan ^a   Heo, Dae Seog ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Cytotoxic chemotherapy; EGFR mutation; Gemcitabine; Taxane

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84863774484     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.020     Document Type: Article

References (25)

1. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
2. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
4. Park K., Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 2006, 22:561-573.
5. Han S.W., Kim T.Y., Hwang P.G., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
6. Chou T.-Y., Chiu C.-H., Li L.-H., et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005, 11:3750-3757.
7. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004, 22:785-794.
8. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004, 22:777-784.
9. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
10. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007, 25:1545-1552.
11. Mitsudomi T., Kosaka T., Endoh H., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
12. Douillard J.Y., Shepherd F.A., Hirsh V., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
13. Yoshimasu T., Oura S., Ohta F., et al. Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. J Thorac Oncol 2011, 6:1658-1662.
14. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
15. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
16. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
17. Kalikaki A., Koutsopoulos A., Hatzidaki D., et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010, 69:110-115.
18. Wu M., Zhao J., Song S.W., et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2010, 67:343-347.
19. Wu J.Y., Shih J.Y., Yang C.H., et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer 2010, 126:247-255.
20. Lee J., Park K., Kim S., Lee D., Kim H., Han J. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009, 4. abst PRS.4.
21. Riely G.J., Pao W., Pham D., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:839-844.
22. Lee J.O., Kim T.M., Lee S.H., et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011, 6:1474-1480.
23. Camidge D.R., Kono S.A., Lu X., et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011, 6:774-780.
24. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
25. Reynolds C., Obasaju C., Schell M.J., et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27:5808-5815.